文献速递肝病消化道出血

以静脉曲张出血为首发失代偿事件的肝硬化患者进一步失代偿风险与生存评估

Assessing the Risk of Further Decompensation and Survival in Patients With Cirrhosis With Variceal Bleeding as Their First Decompensation Event.
PubMed 文献 · Am J Gastroenterol · 2022-09-16

单中心回顾性研究纳入463例以急性静脉曲张出血为首发失代偿事件、其他方面代偿的肝硬化患者,中位随访42个月,292例发生进一步失代偿,5年生存率病毒性91%、非病毒性80.1%(P=0.062),早期进一步失代偿、活动性饮酒和高白细胞计数预测生存不良。

要点

  • 早期进一步失代偿(<6周)患者死亡率52.5%,高于晚期失代偿的20.2%(P<0.001)。
  • 活动性饮酒(HR 9)、高白细胞计数(HR 2.5)、早期失代偿(HR 6.2)预测生存不良。

核心结论

  • 尽管进一步失代偿发生率高,但在无早期进一步失代偿和活动性饮酒的情况下,各病因肝硬化患者5年生存率均超过80%。
  • 病毒性与非病毒性肝硬化患者生存率相似(5年生存率91% vs 80.1%,P=0.062)。

研究设计与样本

  • 单中心回顾性研究,纳入463例以急性静脉曲张出血为首发失代偿事件、其他方面代偿的肝硬化患者。
  • 采用竞争风险分析估计各失代偿事件发生率和生存率,并识别不良结局危险因素。

主要发现

  • 中位年龄47.4(13.2)岁,86.5%为男性,主要病因为酒精性肝病(42.3%)和病毒性肝硬化(22.4%),基线MELD评分中位数14(11-15)。
  • 中位随访42(24-62)个月,292例发生进一步失代偿:腹水283例(96.9%)、再出血157例(53.8%)、肝性脑病71例(24.3%)。
  • 慢加急性肝衰竭在非病毒性肝硬化中更常见(Gray检验,P=0.042),其他事件在不同病因间频率相似。
  • 早期进一步失代偿(首发静脉曲张出血事件后<6周)患者40例,死亡率52.5%,高于晚期失代偿的20.2%(P<0.001)。
  • 活动性饮酒(HR 9 [5.31-15.3],P<0.001)、就诊时高白细胞计数(HR 2.5 [1.4-4.4],P=0.001)、早期失代偿(HR 6.2 [3.6-10.6],P<0.001)预测生存不良。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Limited data exist on long-term outcomes of patients with compensated cirrhosis presenting with acute variceal bleeding (AVB) as an index and lone decompensating event. This study aimed to evaluate the incidence of further decompensation, survival, and risk factors of mortality in these patients. METHODS: Patients with otherwise compensated cirrhosis presenting with AVB as their index decompensating event (n = 463) were analyzed in this single-center retrospective study. The incidence of individual decompensation events and survival was estimated using competing risk analysis. Risk factors for poor outcomes were identified. RESULTS: The mean age was 47.4 (13.2) years, with most patients (86.5%) being males. Alcohol-related liver disease (42.3%) and viral cirrhosis (22.4%) were the main etiologies with a median Model for End-Stage Liver Disease score of 14 (11-15) at baseline. Over a median follow-up of 42 (24-62) months, 292 patients experienced further decompensations: ascites (n = 283; 96.9%), rebleeding (n = 157; 53.8%), and hepatic encephalopathy (n = 71; 24.3%). Most events occurred with similar frequency across different etiologies, except acute-on-chronic liver failure, which was more common in nonviral cirrhosis (Gray test, P = 0.042). Patients with viral and nonviral cirrhosis had similar survival (5-year survival: 91% and 80.1%, respectively; P = 0.062). Patients with early further decompensations (onset <6 weeks of index AVB event) (n = 40) had a higher mortality (52.5% vs 20.2% for late decompensations; P < 0.001). Active alcohol consumption (hazard ratio [HR]: 9 [5.31-15.3], P < 0.001), high white blood cell count at presentation (HR: 2.5 [1.4-4.4], P = 0.001), and early decompensation (HR: 6.2 [3.6-10.6], P < 0.001) predicted poor survival. DISCUSSION: Despite a high incidence of further decompensation, 5-year survival of patients at this stage of cirrhosis is more than 80% across all etiologies in the absence of early further decompensation and active alcohol consumption.

来源:Am J Gastroenterol,查看原文。版权归原作者所有。

引用

  1. Gupta A, Rana R, Agarwal S, et al. Assessing the Risk of Further Decompensation and Survival in Patients With Cirrhosis With Variceal Bleeding as Their First Decompensation Event. Am J Gastroenterol. 2022. PMID: 36114777. doi:10.14309/ajg.0000000000002018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。